Approved indications (U.S.): Avzivi is FDA‑approved, in combination with specific chemotherapy regimens, for adults with metastatic colorectal cancer, unresectable locally advanced/recurrent/metastatic non‑squamous non‑small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent/recurrent/metastatic cervical cancer, and platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Off‑label uses and evidence: As a biosimilar to bevacizumab (Avastin), Avzivi may be considered by clinicians in place of other bevacizumab products for additional advanced solid tumors or in settings where bevacizumab is used off‑label; evidence for these uses comes mainly from trials of reference bevacizumab and real‑world experience, and such use is not specifically FDA‑approved or standard for every patient.

Efficacy expectations: When added to chemotherapy, bevacizumab‑type drugs typically offer modest but clinically meaningful improvements in tumor shrinkage rates and the time before the cancer grows or spreads again, and in some cancers a survival benefit; effects are usually assessed on scans after about 6–12 weeks of treatment rather than by how a patient feels day to day.

Comparison to other similar drugs: As an approved biosimilar, Avzivi is required to have no clinically meaningful differences in safety, purity, or potency compared with Avastin; head‑to‑head studies have shown similar response rates and outcomes, so it is generally expected to work and perform like other bevacizumab products while potentially offering cost or access advantages.

Typical dosing by condition (adults): Doses are based on body weight and given as an IV infusion, usually every 2 or 3 weeks together with chemotherapy. Common regimens include about 5–10 mg/kg every 2 weeks for metastatic colorectal cancer, 15 mg/kg every 3 weeks for first‑line non‑squamous non‑small cell lung cancer or metastatic cervical cancer, and 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks for recurrent glioblastoma, metastatic renal cell carcinoma, and certain platinum‑resistant recurrent ovarian, fallopian tube, or primary peritoneal cancers; your oncologist chooses the exact schedule.

How it is given: Avzivi is prepared and diluted in 0.9% sodium chloride by healthcare staff and given only as an intravenous infusion in an infusion center or hospital. The first infusion usually runs over about 90 minutes; if tolerated, later infusions may be shortened to 60 minutes and then to about 30 minutes. It is never given as a rapid IV push or mixed with dextrose solutions.

Special dosing instructions: Treatment typically continues as long as there is clinical benefit and side effects remain manageable. Avzivi is usually withheld for at least 28 days before and after major surgery and may be delayed, reduced in frequency, or permanently stopped for severe high blood pressure, serious bleeding, gastrointestinal perforation, wound‑healing problems, or other serious toxicities as directed by the oncology team.

Missed doses: If an infusion appointment is missed, patients should contact their oncology clinic as soon as possible to reschedule; doses are not doubled, and the schedule is adjusted by the care team rather than by the patient.

Overdose: There is no specific antidote for Avzivi overdose; management consists of close monitoring for severe hypertension, bleeding, clotting events, kidney problems, and other toxicities, and providing intensive supportive care as needed in a medical facility.

Common side effects: Frequently reported effects include high blood pressure, fatigue or weakness, headache, diarrhea, abdominal pain, decreased appetite, nosebleeds, dry or peeling skin, mouth sores, and protein in the urine; these often start within the first few treatment cycles and range from mild to moderate, though blood pressure and urine changes may require medicines or treatment breaks.

Serious or rare adverse effects: Important but less common risks include gastrointestinal perforation (a hole or tear in the stomach or intestines), fistula formation, severe bleeding (for example coughing or vomiting blood, heavy vaginal or gastrointestinal bleeding, brain or nose bleeds), blood clots or stroke, heart attack, heart failure, severe high blood pressure or hypertensive crisis, kidney damage with heavy protein loss, wound‑healing problems around surgeries, and a rare brain condition called posterior reversible encephalopathy syndrome (PRES) with seizures, vision changes, or confusion; any sudden severe pain, shortness of breath, chest pain, severe headache, confusion, or heavy bleeding needs emergency attention.

Warnings and precautions: Avzivi should not be used during pregnancy because it may harm an unborn baby, and effective contraception is recommended during treatment and for at least 6 months after the last dose; breastfeeding is not advised during treatment and for 6 months afterward. Use in children is not established. People with uncontrolled high blood pressure, recent major surgery, a history of serious bleeding, significant heart or vascular disease, or severe kidney problems need extra caution and close monitoring, and the medicine is typically held for at least 28 days before and after major surgery until wounds are healed.

Relative safety profile: The safety pattern of Avzivi is expected to match that of reference bevacizumab, with similar rates and types of side effects; it is not more toxic than other bevacizumab products but carries higher risks of bleeding, clotting, high blood pressure, and wound‑healing issues than many non‑anti‑VEGF cancer drugs.

Reporting side effects and safety updates: Side effects should be reported promptly to the treating oncology team and can also be reported directly to the FDA through the MedWatch program (online or by phone); updated safety information and alerts are posted by the FDA and the manufacturer on their official websites.

Drug and supplement interactions: Avzivi is a monoclonal antibody and is not significantly processed through liver enzyme pathways, so classic drug–drug interactions are uncommon; however, medicines that increase bleeding risk (such as full‑dose anticoagulants, antiplatelet drugs, and chronic high‑dose NSAIDs) or affect blood pressure can heighten the risks of bleeding or hypertension and must be used with care. Always tell your oncology team about all prescriptions, over‑the‑counter medicines, vitamins, and herbal supplements you take.

Food, alcohol, and procedures: There are no specific food restrictions with Avzivi, but limiting excess alcohol is generally advised because it can worsen blood pressure and liver problems. Because Avzivi can impair wound healing and increase bleeding, dentists and surgeons should be informed before any procedure; the oncology team may advise holding treatment for a period before and after major operations or invasive procedures.

Conditions requiring extra caution: People with uncontrolled or severe hypertension, a history of stroke, heart attack, serious blood clots, major recent surgery or wounds that have not healed, significant kidney disease with proteinuria, or prior gastrointestinal perforation or fistulas require careful risk–benefit assessment and closer monitoring, and Avzivi may be avoided or stopped if risks outweigh benefits.

Monitoring needs: During treatment, clinicians typically check blood pressure regularly, perform urine tests for protein, and order blood tests to assess kidney function, blood counts, and sometimes heart function; imaging studies and physical exams are also used to follow tumor response and detect complications.

Q: Is Avzivi the same as Avastin?
A: Avzivi (bevacizumab-tnjn) is an FDA‑approved biosimilar to Avastin, meaning it is highly similar and has no clinically meaningful differences in safety or effectiveness compared with Avastin, but it is made by a different manufacturer.

Q: How will I receive Avzivi and how long does an infusion take?
A: Avzivi is given through a vein in an infusion center or hospital, with the first dose usually infused over about 90 minutes and later doses shortened to about 60 minutes and then 30 minutes if you tolerate them well.

Q: How soon might Avzivi start working on my cancer?
A: Many people have their first restaging scans after roughly 6–12 weeks of treatment, and doctors look at those images plus symptoms and lab results to see whether the tumor has shrunk or stopped growing.

Q: How long will I need to stay on Avzivi?
A: Treatment usually continues as long as your cancer is controlled and side effects remain acceptable, and it is stopped if the cancer clearly worsens or serious toxicity occurs.

Q: Can I get vaccines or drink alcohol while on Avzivi?
A: Inactivated (non‑live) vaccines are generally allowed, but you should avoid live vaccines and always discuss timing with your oncologist; moderate alcohol may be permissible for some people, but because of blood pressure and bleeding risks it should be limited and cleared with your care team.

Q: Is Avzivi safe during pregnancy or breastfeeding?
A: Avzivi can harm an unborn baby and is not recommended during pregnancy or while breastfeeding, so effective contraception is advised during treatment and for at least 6 months after the last dose, and breastfeeding should also be avoided during that period.